drugset / Trial / NCT01795859

First Time Use of SD-809 in Huntington Disease

NCT01795859

Phase 3 Completed 90 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.

Timeline

Start
2013-08-05
Primary completion
2014-12-05
Completion
2014-12-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Deutetrabenazine Unknown 6 mg
Subject Deutetrabenazine Unknown 9 mg
Subject Deutetrabenazine Unknown 12 mg

Indications